^
3ms
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
CRB-601
almost2years
CRB-601, an avβ8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment (AACR 2023)
CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors. CRB-601 antitumor activity correlated to increased αvβ8 RO and downregulation of TGFβ signaling. Investigational New Drug (IND) enabling studies are in progress.
Immune cell
|
IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
CRB-601